radiopharmaceuticals

Findings show extended progression-free survival for people with meningiomas who received a radiopharmaceutical approved for neuroendocrine tumors.

Dr. Oliver Sartor discusses treatment for prostate cancer that has spread to other parts of the body and the use of PSA tests to reduce risk.